Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.
CytoKi Pharma ApS, a discovery stage biotech company, develops treatments for epithelial injury based diseases with an unmet medical need. The company was founded in 2019 and is based in Værløse, Denmark.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
SparingVision SAS is a biotechnology company based in Paris, France, focused on discovering and developing gene therapy-based treatments for blinding inherited retinal diseases. Founded in 2016, the company is working on SPVN06, a gene-independent therapy aimed at treating retinitis pigmentosa, the most common form of inherited retinal degeneration. This condition affects nearly 2 million people globally and currently lacks comprehensive treatment options for its various genetic forms. SparingVision’s efforts aim to provide innovative solutions for patients suffering from these debilitating diseases, enabling healthcare professionals to offer improved care for those at risk of blindness.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Babyscripts is a digital health platform focused on enhancing prenatal and postpartum care through a virtual approach. Designed to strengthen the relationship between patients and healthcare providers, it offers a mobile app that guides expectant mothers through their pregnancy journey with tasks related to nutrition, exercise, and other relevant behaviors. Upon enrollment by their OBGYN, patients receive a Mommy Kit, which includes internet-enabled devices such as a weight scale and blood pressure cuff. This setup allows mothers to monitor their health at home while staying connected with their healthcare providers. The app automatically captures health readings and compliance data, facilitating real-time feedback and intervention. Babyscripts collaborates with major health systems to improve care for high-risk pregnancies, continuously refining its offerings to reach more expecting mothers and address critical issues such as maternal mortality.
Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Inbiomotion SL, a personalized medicine company, develops biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company focuses on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. It develops biomarker in breast cancer primary tumors for predicting the risk of bone relapse. Inbiomotion SL was founded in 2010 and is based in Barcelona, Spain.
Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
DermaLumics S.L. is a medical device company based in Madrid, Spain, that specializes in advanced optical imaging technology for dermatology. Founded in 2014, the company manufactures NITID, a non-invasive and portable skin imaging solution that utilizes Optical Coherence Tomography (OCT) to assist dermatologists in diagnosing skin conditions, including skin cancer. In addition to its imaging products, DermaLumics offers consulting and support services to enhance the application of its technology in clinical practice. The company's mission is to improve skincare by providing innovative diagnostic tools that enable healthcare professionals to better assess the health of their patients' skin, hair, and nails.
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Inbiomotion SL, a personalized medicine company, develops biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company focuses on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. It develops biomarker in breast cancer primary tumors for predicting the risk of bone relapse. Inbiomotion SL was founded in 2010 and is based in Barcelona, Spain.
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.
SabirMedical S.L. is a biomedical research and development company based in Barcelona, Spain, founded in 2007. The company specializes in developing innovative technologies for diagnostics and patient care, particularly in the area of cardiovascular monitoring. Its offerings include non-invasive blood pressure monitoring systems that utilize pulse oximetry, designed for hospital, ambulatory, and home use. SabirMedical operates from the Bioincubator PCB-Santander space at Barcelona Science Park, emphasizing its commitment to advancing healthcare through technology.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.